Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 26;25(1):100.
doi: 10.3390/molecules25010100.

Efficient Synthesis of Purine Nucleoside Analogs by a New Trimeric Purine Nucleoside Phosphorylase from Aneurinibacillus migulanus AM007

Affiliations

Efficient Synthesis of Purine Nucleoside Analogs by a New Trimeric Purine Nucleoside Phosphorylase from Aneurinibacillus migulanus AM007

Gaofei Liu et al. Molecules. .

Abstract

Purine nucleoside phosphorylases (PNPs) are promising biocatalysts for the synthesis of purine nucleoside analogs. Although a number of PNPs have been reported, the development of highly efficient enzymes for industrial applications is still in high demand. Herein, a new trimeric purine nucleoside phosphorylase (AmPNP) from Aneurinibacillus migulanus AM007 was cloned and heterologously expressed in Escherichia coli BL21(DE3). The AmPNP showed good thermostability and a broad range of pH stability. The enzyme was thermostable below 55 °C for 12 h (retaining nearly 100% of its initial activity), and retained nearly 100% of the initial activity in alkaline buffer systems (pH 7.0-9.0) at 60 °C for 2 h. Then, a one-pot, two-enzyme mode of transglycosylation reaction was successfully constructed by combining pyrimidine nucleoside phosphorylase (BbPyNP) derived from Brevibacillus borstelensis LK01 and AmPNP for the production of purine nucleoside analogs. Conversions of 2,6-diaminopurine ribonucleoside (1), 2-amino-6-chloropurine ribonucleoside (2), and 6-thioguanine ribonucleoside (3) synthesized still reached >90% on the higher concentrations of substrates (pentofuranosyl donor: purine base; 20:10 mM) with a low enzyme ratio of BbPyNP: AmPNP (2:20 μg/mL). Thus, the new trimeric AmPNP is a promising biocatalyst for industrial production of purine nucleoside analogs.

Keywords: enzyme ratio; purine nucleoside analogs; thermostability; trimeric nucleoside phosphorylase.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Phylogenetic analysis of purine nucleoside phosphorylases (PNPs). AhPNP (GenBank:WP_049045821) from Aeromonas hydrophila; BcPNP (GenBank:WP_098273438) from Bacillus cereus; BhPNP (GenBank: WP_010897696) from Bacillus halodurans; BtPNP (GenBank: AAX46392) from Bos taurus; Bs3PNP (GenBank: WP_015714207) from Bacillus subtilis; Bs6PNP (GenBank: WP_044428467) from Bacillus subtilis; DrPNP (GenBank: NP_998476) from Danio rerio; EcPNP (GenBank: AAN83888) from Escherichia coli; FhPNP (GenBank: XP_012736771) from Fundulus heteroclitus; GsPNP (GenBank: WP_053414649) from Geobacillus stearothermophilus; HaPNP (GenBank:KFP95377) from Haliaeetus albicilla; HsPNP (GenBank: NP_000261) from Homo sapiens; MmPNP (GenBank: NP_038660) from Mus musculus; SsPNP (GenBank: WP_009988635) from Sulfolobus solfataricus; StPNP (GenBank: WP_011681178) from Streptococcus thermophilus; TtPNP (GenBank: WP_096412123) from Thermus thermophilus; and XtPNP (GenBank: NP_001006720) from Xenopus tropicalis.
Figure 2
Figure 2
Molecular weight analysis of AmPNP. (a) Dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of purified AmPNP. Lane M: marker; Lane 1: crude enzymes; Lane 2: enzyme of AmPNP purified by Ni2+ column. (b) Analysis of AmPNP by gel filtration chromatography. The condition was conducted as following: an ÄKTA pure system and a column Superdex 200 Increase 10/300 GL were used. The standard proteins and the purified AmPNP sample were dissolved in the buffer (0.01 M phosphate buffer, 0.14 M NaCl, pH 8.0) with the final concentration of 2 mg/mL, respectively. For analysis, the flow rate was set at 0.3 mL/min and the inject volume was 500 μL.
Scheme 1
Scheme 1
Phosphorylation of inosine with AmPNP.
Figure 3
Figure 3
Effects of temperature and pH on the activity and stability of AmPNP. (a) Effect of temperature on the activity of AmPNP. The highest activity was set to 100%. (b) Effects of temperature on stability of AmPNP. The initial activity was set to 100%. (c) Effect of pH on the activity determined by assaying the activity at 60 °C in 10 mM Na2HPO4/KH2PO4 buffer. The highest activity was set to 100%. (d) Effect of pH on stability determined by assaying the residual activity of AmPNP after 2 h at 60 °C and different pH values in 10 mM Na2HPO4/KH2PO4 buffer. The highest activity was set to 100%. The activity of AmPNP was determined in 10 mM Na2HPO4/KH2PO4 buffer (pH 8.0) with 10 mM inosine.
Scheme 2
Scheme 2
Enzymatic synthesis of 2-amino-6-chloropurine ribonucleoside.
Figure 4
Figure 4
Effect of temperature and pH on biosynthesis of 2-amino-6-chloropurine ribonucleoside BbPyNP: AmPNP in a ratio of 2:20 μg/mL. The reaction mixture (1.0 mL) contained 20 mM uridine and 10 mM 2-amino-6-chloropurine. (a) The reaction was conducted in a thermostatic oscillator at a pH of 8.0 (20 mM Na2HPO4/KH2PO4) with temperature ranging from 30 °C to 65 °C for 36 h. (b) The reaction was carried out at a temperature of 55 °C for 60 h in 20 mM Na2HPO4/KH2PO4 buffer systems with pH ranging from 5.0 to 8.0.
Figure 5
Figure 5
Effect of the ratio of BbPyNP: AmPNP on biosynthesis of 2-amino-6-chloropurine ribonucleoside. Process for synthesis of 2-amino-6-chloropurine ribonucleoside was shown in Scheme 2. Using 20 mM uridine and 10mM 2-amino-6-chloropurine, the reaction mixture (1.0 mL) contained purified BbPyNP (85 IU/mg for uridine) and purified AmPNP (83 IU/mg) at different ratios (the concentration of AmPNP was set at 20 μg/mL). The reaction was carried out at pH 7.0 (20 mM Na2HPO4/KH2PO4) and a temperature of 55 °C for 36 h, followed by analysis.

Similar articles

Cited by

References

    1. Seley-Radtke K.L., Yates M.K. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antivir. Res. 2018;154:66–86. doi: 10.1016/j.antiviral.2018.04.004. - DOI - PMC - PubMed
    1. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3:415–424. doi: 10.1016/S1470-2045(02)00788-X. - DOI - PubMed
    1. Tănase C.I., Drăghici C., Hanganu A., Pintilie L., Maganu M., Volobueva A., Sinegubova E., Zarubaev V.V., Neyts J., Jochmans D., et al. New HSV-1 Anti-Viral 1′-Homocarbocyclic Nucleoside Analogs with an Optically Active Substituted Bicyclo[2.2. 1]Heptane Fragment as a Glycoside Moiety. Molecules. 2019;24:2446 - PMC - PubMed
    1. Robak T., Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr. Pharm. Des. 2012;18:3373–3388. doi: 10.2174/138161212801227005. - DOI - PubMed
    1. Bonate P.L., Arthaud L., Cantrell W.R., Jr. Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat. Rev. Drug Discov. 2006;5:855–863. doi: 10.1038/nrd2055. - DOI - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources